ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Neutral
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Telephone
61.3.9123.1140
Address
Level 5 90 William Street Melbourne, Victoria (VIC) 3000
Description
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.43
Trade Value (12mth)
AU$118,817.00
1 week
0%
1 month
-17.5%
YTD
77.42%
1 year
53.04%
All time high
15.95
EPS 3 yr Growth
-10.50%
EBITDA Margin
N/A
Operating Cashflow
-$7m
Free Cash Flow Return
-42.40%
ROIC
-40.50%
Interest Coverage
-187.70
Quick Ratio
7.90
Shares on Issue (Fully Dilluted)
365m
HALO Sector
Healthcare
Next Company Report Date
01-Jun-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
08 September 25 |
Notification of cessation of securities - ATX
×
Notification of cessation of securities - ATX |
|
08 September 25 |
Change of Director's Interest Notice - Jane Bell
×
Change of Director's Interest Notice - Jane Bell |
|
08 September 25 |
Change of Director's Interest Notice - Robert Peach
×
Change of Director's Interest Notice - Robert Peach |
|
08 September 25 |
Change of Director's Interest Notice - Chris Burns
×
Change of Director's Interest Notice - Chris Burns |
|
08 September 25 |
Change of Director's Interest Notice - Warwick Tong
×
Change of Director's Interest Notice - Warwick Tong |
|
04 September 25 |
FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL
×
FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL |
|
02 September 25 |
NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA
×
NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA |
|
02 September 25 |
Notification of cessation of securities - ATX
×
Notification of cessation of securities - ATX |
|
01 September 25 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
|
01 September 25 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
|
01 September 25 |
Notice under Section 708A(5)(e) of the Corporations Act
×
Notice under Section 708A(5)(e) of the Corporations Act |
|
01 September 25 |
Notification regarding unquoted securities - ATX
×
Notification regarding unquoted securities - ATX |
|
01 September 25 |
Notification regarding unquoted securities - ATX
×
Notification regarding unquoted securities - ATX |
|
29 August 25 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
|
29 August 25 |
AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
×
AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL |
|
27 August 25 |
Managing Director's Presentation to AGM
×
Managing Director's Presentation to AGM |
|
27 August 25 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
|
26 August 25 |
Amplia Share Purchase Plan Raises $2.65 Million
×
Amplia Share Purchase Plan Raises $2.65 Million |
|
07 August 25 |
Presentation - Targeting Pancreatic Cancer and Beyond
×
Presentation - Targeting Pancreatic Cancer and Beyond |
|
06 August 25 |
Positive ACCENT Trial Topline Data Released
×
Positive ACCENT Trial Topline Data Released |
|
01 August 25 |
Change of Registered Office and Principal Place of Business
×
Change of Registered Office and Principal Place of Business |
|
01 August 25 |
Share Purchase Plan Prospectus
×
Share Purchase Plan Prospectus |
|
31 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
30 July 25 |
Australian Ethics Clearance for Pancreatic Cancer Trial
×
Australian Ethics Clearance for Pancreatic Cancer Trial |
|
30 July 25 |
Change in substantial holding
×
Change in substantial holding |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
